Bevacizumab Concomitant with Chemotherapy is Effective in Treating Chinese Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer

Objectives: To retrospectively review the safety and clinical efficacy of bevacizumab concomitant withchemotherapy in Chinese patients with advanced non-squamous non-small cell lung cancer (NSNSCLC).
Methods:Clinical data for 79 patients with NSNSCLC who received bevacizumab concomitant with chemotherapy inChinese PLA General Hospital from April 28th 2009 to May 5th 2013 were retrospectively reviewed to analyzethe clinical efficacy including disease control rate (DCR), overall response rate (ORR), progression-free survival(PFS), overall survival (OS), the Eastern Cooperative Oncology Group (ECOG) score and the safety.
Results:The Eastern Cooperative Oncology Group (ECOG) score was 0-2. By the final cutoff date (June 9, 2013), 54(68.4%) patients had disease progression and 37 (46.8%) died. The ORR was 32.9% and the DCR was 83.5%.The ORR of the first-, second-, and third- or later-line treatments were 51.4%, 25.0% and 12.5%, while the DCRwere 94.3%, 80.0% and 70.8%, respectively. The median OS (mOS) and PFS (mPFS) were 13.5 and 5.83 months,respectively. The mOS of patients with the first-, second-, and third- or later- line treatments were 16.2, 10.9and8.30 months, while the mPFS were 7.27, 5.90 and 5.17 months, respectively. Chemotherapy-related adverseevents included myelosuppression, vomiting, hepatic dysfunction and renal dysfunction, while the commonserious bevacizumab-related adverse events were thromboembolic problems, gastrointestinal perforation andreversible posterior leukoencephalopathy syndrome, which could be well managed.
Conclusions: Bevacizumabconcomitant with chemotherapy is effective and the related toxicity can be well tolerated in Chinese patientswith NSNSCLC.